pharmaphorum
JANUARY 17, 2023
Its vocal biomarkers are already being used to gauge the effect of drug treatments for dementia, including in the phase 2 TAURIEL trial of Roche/AC Immune’s’s tau protein-targeted antibody semorinemab. million) to its top-line in 2023 with “considerable growth” next year.
pharmaphorum
APRIL 29, 2021
Nefecon aims to sidestep that issue by delivering the steroid at the site where it is needed – immune tissue called Peyer’s patches – that is found in the ileum, the final section of small intestine. Steroids in particular can have side effects however, including weight gain and infections.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
SEPTEMBER 12, 2023
tumor formation, immune reactions, and therapy failure). Albutein appears to be on track to be the first therapeutic approved for DC, with a projected US launch date in Q1 2026. HepaStem is projected to hit the US market in Q1 2027, while BioVie’s BIV201 is anticipated to be marketed in Q4 2028.
Express Pharma
MARCH 20, 2023
India is preparing to include human papillomavirus (HPV) vaccines as part of the government-driven public immunization program popularly known as the Universal Immunization Program (UIP). The Indian government is expected to roll out a global tender of 160 million doses from various HPV vaccine players for supply until 2026.
Pharmaceutical Technology
JULY 18, 2022
Spanning to March 2026, the four-year agreement comprises the delivery of nearly 80 million doses of adjuvanted pandemic influenza vaccine, Arepanrix, and at least four million doses of seasonal influenza vaccine, Flulaval Tetra, each year. H1N1, also called Swine Flu is the latest influenza pandemic in the country.
Pharmaceutical Business Review
OCTOBER 1, 2024
A human monoclonal antibody, Ustekinumab acts on the interleukin-12 and interleukin-23 cytokines which hold a key role in inflammatory and immune responses. Fresenius Kabi and Formycon signed an international commercialisation deal in February last year for the ustekinumab biosimilar candidate for various markets across the globe.
pharmaphorum
APRIL 23, 2021
The ileum is the site of immune tissue called Peyer’s patches, which are thought to play a key role in the autoimmune response seen in IgAN. Analysts at EvaluatePharma reckon however that Nefecon will lead the market if approved, with estimated sales of around $575 million in 2026.
Expert insights. Personalized for you.
105 
Let's personalize your content